{"?xml":{"@version":"1.0"},"edm:RDF":{"@xmlns:dc":"http://purl.org/dc/elements/1.1/","@xmlns:edm":"http://www.europeana.eu/schemas/edm/","@xmlns:wgs84_pos":"http://www.w3.org/2003/01/geo/wgs84_pos","@xmlns:foaf":"http://xmlns.com/foaf/0.1/","@xmlns:rdaGr2":"http://rdvocab.info/ElementsGr2","@xmlns:oai":"http://www.openarchives.org/OAI/2.0/","@xmlns:owl":"http://www.w3.org/2002/07/owl#","@xmlns:rdf":"http://www.w3.org/1999/02/22-rdf-syntax-ns#","@xmlns:ore":"http://www.openarchives.org/ore/terms/","@xmlns:skos":"http://www.w3.org/2004/02/skos/core#","@xmlns:dcterms":"http://purl.org/dc/terms/","edm:WebResource":[{"@rdf:about":"http://www.dlib.si/stream/URN:NBN:SI:doc-PZIJ8AAW/ae3333a5-38d8-4a16-b406-a540d1944abf/PDF","dcterms:extent":"170 KB"},{"@rdf:about":"http://www.dlib.si/stream/URN:NBN:SI:doc-PZIJ8AAW/0cb0f5da-5a79-499a-bff5-eee98bf7473b/TEXT","dcterms:extent":"32 KB"}],"edm:TimeSpan":{"@rdf:about":"2005-2025","edm:begin":{"@xml:lang":"en","#text":"2005"},"edm:end":{"@xml:lang":"en","#text":"2025"}},"edm:ProvidedCHO":{"@rdf:about":"URN:NBN:SI:doc-PZIJ8AAW","dcterms:isPartOf":[{"@rdf:resource":"https://www.dlib.si/details/URN:NBN:SI:spr-8ER5ZBJN"},{"@xml:lang":"sl","#text":"Farmacevtski vestnik"}],"dcterms:issued":"2015","dc:creator":["Locatelli, Igor","Petrovič, Maja"],"dc:format":[{"@xml:lang":"sl","#text":"številka:5"},{"@xml:lang":"sl","#text":"letnik:66"},{"@xml:lang":"sl","#text":"str. 414-422"}],"dc:identifier":["ISSN:0014-8229","COBISSID:4007025","URN:URN:NBN:SI:doc-PZIJ8AAW"],"dc:language":"sl","dc:publisher":{"@xml:lang":"sl","#text":"Slovensko farmacevtsko društvo"},"dc:subject":[{"@xml:lang":"sl","#text":"antagonisti endotelinskih receptorjev"},{"@xml:lang":"sl","#text":"pljučna arterijska hipertenzija"},{"@xml:lang":"sl","#text":"primerno zdravljenje"},{"@xml:lang":"sl","#text":"prostaciklin"},{"@xml:lang":"sl","#text":"specifična zdravila"},{"@xml:lang":"sl","#text":"uporaba zdravil"},{"@rdf:resource":"http://www.wikidata.org/entity/Q412050"}],"dcterms:temporal":{"@rdf:resource":"2005-2025"},"dc:title":{"@xml:lang":"sl","#text":"Zdravila za zdravljenje pljučne arterijske hipertenzije| Medicines used in the treatment of pulmonary arterial hypertension|"},"dc:description":[{"@xml:lang":"sl","#text":"Pulmonary arterial hypertension (PAH) is a rare, chronic and progressive disease of various aetiologies, and affects pulmonary vessels. Irrespective of the cause, pathological changes to pulmonary vasculature lead to right ventricular dysfunction and premature death. The development of new drugs in the treatment of PAH has been accelerated over the last two decades, also on the initiative of the European Commission. In the last three years two new drugs for the treatment of PAH were approved, while the approval for the third drug is anticipated. Specific drug therapy used in the treatment of PAH is presented in the article, namely prostacyclin analogues, selective prostacyclin agonists, endothelin receptor antagonists, phosphodiesterase 5 inhibitors, and soluble guanylate cyclase stimulators"},{"@xml:lang":"sl","#text":"Pljučna arterijska hipertenzija (PAH) je redka, kronična, progresivna bolezen raznovrstnih etiologij, ki prizadene pljučno žilje. Ne glede na vzrok pojava bolezni, patološke spremembe pljučnega žilja sčasoma vodijo do popuščanja desnega srčnega prekata in prezgodnje smrti. V zadnjih dveh desetletjih je bila hitrost razvoja specifičnih zdravil za zdravljenje PAH pospešena, tudi napobudo Evropske komisije. V samo zadnjih treh letih je sta bili odobreni dvenovi zdravili za zdravljenje PAH, medtem ko odobritev za tretje zdravilo odobritev še pričakujemo. V prispevku predstavljamo pregled specifičnih zdravil za zdravljenje PAH, ki spadajo v skupino analogov prostaciklina, selektivnih agonistov prostaciklinskih receptorjev, antagonistov endotelinskihreceptorjev, selektivnih zaviralcev fosfodiesteraze tipa 5 ter spodbujevalcev topne gvanilat ciklaze"}],"edm:type":"TEXT","dc:type":[{"@xml:lang":"sl","#text":"znanstveno časopisje"},{"@xml:lang":"en","#text":"journals"},{"@rdf:resource":"http://www.wikidata.org/entity/Q361785"}]},"ore:Aggregation":{"@rdf:about":"http://www.dlib.si/?URN=URN:NBN:SI:doc-PZIJ8AAW","edm:aggregatedCHO":{"@rdf:resource":"URN:NBN:SI:doc-PZIJ8AAW"},"edm:isShownBy":{"@rdf:resource":"http://www.dlib.si/stream/URN:NBN:SI:doc-PZIJ8AAW/ae3333a5-38d8-4a16-b406-a540d1944abf/PDF"},"edm:rights":{"@rdf:resource":"http://rightsstatements.org/vocab/InC/1.0/"},"edm:provider":"Slovenian National E-content Aggregator","edm:intermediateProvider":{"@xml:lang":"en","#text":"National and University Library of Slovenia"},"edm:dataProvider":{"@xml:lang":"sl","#text":"Slovensko farmacevtsko društvo"},"edm:object":{"@rdf:resource":"http://www.dlib.si/streamdb/URN:NBN:SI:doc-PZIJ8AAW/maxi/edm"},"edm:isShownAt":{"@rdf:resource":"http://www.dlib.si/details/URN:NBN:SI:doc-PZIJ8AAW"}}}}